中国人群中抗结核药物引发肝损伤的易感基因标记研究
收稿日期: 2019-11-24
修回日期: 2019-12-26
网络出版日期: 2020-02-26
基金资助
国家自然科学基金项目编号(81773818);国家自然科学基金项目编号(81273596);国家自然科学基金项目编号(30900799);国家自然科学基金项目编号(81671326);上海市浦江人才计划项目资助编号(17PJD020)
Study on hereditary susceptibility genetic markers to anti-tuberculosis drug induced liver injury in Chinese population
Received date: 2019-11-24
Revised date: 2019-12-26
Online published: 2020-02-26
Supported by
Supported by the National Natural Science Foundation of China Nos(81773818);Supported by the National Natural Science Foundation of China Nos(81273596);Supported by the National Natural Science Foundation of China Nos(30900799);Supported by the National Natural Science Foundation of China Nos(81671326);Shanghai Pujiang Program No(17PJD020)
为系统性研究中国人群中抗结核药物引发肝损伤的易感基因标记,本研究以41例抗结核药物引发肝损伤的病人和39例健康对照为研究对象,采用Haloplex捕获测序的方法对其基因组中药物代谢、转运和免疫相关通路的109个基因进行靶向测序。用Plink软件对DNA突变位点与肝损伤的发生进行关联分析,以千人基因组计划东亚人群作为对照组,对显著性位点进行验证,并用SIFT和Polyphen2软件对预测显著关联的位点进行功能预测。结果发现UGT1A4 rs2011404 (χ 2 = 4.6809, P =0.0305)是抗结核药物引发的肝损伤的易感基因标记,且rs2011404突变可能引起UGT1A4蛋白的功能障碍。本研究为临床上对抗结核药物的合理用药提供了有益的参考。
周晨希, 李沫, 怀聪, 贺林, 秦胜营 . 中国人群中抗结核药物引发肝损伤的易感基因标记研究[J]. 遗传, 2020 , 42(4) : 374 -379 . DOI: 10.16288/j.yczz.19-271
To systematically study the susceptible genetic markers for liver injury induced by anti-tuberculosis drugs in the Chinese population, 109 genes related to drug metabolism, transport and immunity were captured by Haloplex capture technique from DNA samples of 41 patients with liver injury induced by anti-tuberculosis drugs and 39 healthy controls, and sequenced completely. Association study was conducted using Plink software. To verify the significant candidate SNPs, the χ 2 study was expanded to the control group from the 1000-person Genome Project of the East Asian population. SIFT and Polyphen2 software were used to predict the functional significance of the associated SNPs. Our results identified the UGT1A4 rs2011404 (χ 2 = 4.6809, P = 0.0305) as a susceptible genetic marker for liver injury induced by anti-tuberculosis drugs, and rs2011404 mutation might contribute to UGT1A4 protein dysfunction. This study has provided a potentially useful reference for establishing the precision medicine in rational uses of anti-tuberculosis drugs in the clinic.
Key words： anti-tuberculosis drug; liver injury; association study; UGT1A4
| [1] | WHO. Global tuberculosis report 2018. 2018. |
| [2] | Zheng W, Ji LD, Xing WH, Tu WW, Xu J . Advances in genome-wide association study of tuberculosis. Hereditas (Beijing), 2013,35(7):823-829. |
| [2] | 郑伟, 季林丹, 邢文华, 涂巍巍, 徐进 , 肺结核全基因组关联研究进展. 遗传, 2013,35(7):823-829. |
| [3] | 肺结核诊断和治疗指南(2001年订). 内科急危重症杂志, 2002,8(4):225-229. |
| [4] | Xia YY, Zhan SY . Systematic review of anti-tuberculosis drug induced adverse reactions in China. Chin J Tubercul Respir Dis, 2007,30(6):419-423. |
| [4] | 夏愔愔, 詹思延 , 国内抗结核药物不良反应发生率的综合分析. 中华结核和呼吸杂志, 2007,30(6):419-423. |
| [5] | Shang PH, Xia YY, Liu FY, Wang XM, Yuan YL, Hu DY, Tu DH, Chen YX, Deng PY, Cheng SM, Zhou L, Ma Y, Zhu LZ, Gao WW, Wang HY, Chen DF, Yang L, He PP, Wu SS, Tang SW, Lv XZ, Shu Z, Zhang Y, Yang ZR, Chen Y, Li N, Sun F, Li XT, He YJ, Garner P, Zhan SY . Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (atli) in china. PLoS One, 2011,6(7):e21836. |
| [6] | Chen R, Wang J, Zhang Y, Tang SW, Zhan SY . Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Arch Toxicol, 2015,89(6):883-897. |
| [7] | Russmann S, Kullak-Ublick GA, Grattagliano I . Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem, 2009,16(23):3041-3053. |
| [8] | Metushi I, Uetrecht J, Phillips E . Mechanism of isoniazid- induced hepatotoxicity: Then and now. Br J Clin Pharmacol, 2016,81(6):1030-1036. |
| [9] | Benichou C, Danan G, Flahault A . Causality assessment of adverse reactions to drugs-ii. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol, 1993,46(11):1331-1336. |
| [10] | Hoofnagle JH, Bj?rnsson ES . Drug-induced liver injury - types and phenotypes. N Engl J Med, 2019,381(3):264-273. |
| [11] | Yu LC, Mao YM, Chen CW . Guidelines for the management of drug-induced liver injury. J Clin Hepatol, 2015,31(11):1752-1769. |
| [11] | 于乐成, 茅益民, 陈成伟 . 药物性肝损伤诊治指南. 临床肝胆病杂志, 2015,31(11):1752-1769. |
| [12] | Wen ZD, Hu GX, Yang J, Chen ZM . Retrospective analysis of 7018 cases of drug-induced liver injury literature. Chin Foreign Med Res, 2016,14(12):64-65. |
| [12] | 温祝杜, 胡国信, 杨剑, 陈智明 . 7018例药物性肝损伤文献回顾性分析. 中外医学研究, 2016,14(12):64-65. |
| [13] | Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD . Cytochrome p450 2e1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 2003,37(4):924-930. |
| [14] | Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD . Polymorphism of the n-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology, 2002,35(4):883-889. |
| [15] | Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP . Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione s-transferase m1 ‘null’ mutation. J Gastroenterol Hepatol, 2001,16(9):1033-1037. |
| [16] | Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E . Pharmacogenetic & pharmacokinetic biomarker for efavirenz based arv and rifampicin based anti-tb drug induced liver injury in tb-hiv infected patients. PLoS One, 2011,6(12):e27810. |
| [17] | Li LM, Chen L, Deng GH, Tan WT, Dan YJ, Wang RQ, Chen WS . SLCO1B1*15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep, 2012,6(1):75-82. |
| [18] | Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK . Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med, 2002,166(7):916-919. |
| [19] | Benoit-Biancamano MO, Adam JP, Bernard O, Court MH, Leblanc MH, Caron P, Guillemette C . A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics, 2009,19(12):945-954. |
| [20] | Chang JC, Liu EH, Lee CN, Lin YC, Yu MC, Bai KJ, Chen HY . UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications. Int J Tuberc Lung Dis, 2012,16(3):376-378. |
| [21] | Gufford BT, Robarge JD, Eadon MT, Gao H, Lin H, Liu Y, Desta Z, Skaar TC . Rifampin modulation of xeno- and endobiotic conjugating enzyme mrna expression and associated micrornas in human hepatocytes. Pharmacol Res Perspect, 2018,6(2):e00386. |
| [22] | Lee SY, Lee JY, Kim YM, Kim SK, Oh SJ . Expression of hepatic cytochrome P450s and UDP-glucuronosyltransferases in PXR and CAR double humanized mice treated with rifampicin. Toxicol Lett, 2015,235(2):107-115. |
| [23] | Cao L, Greenblatt DJ, Kwara A . Inhibitory effects of selected antituberculosis drugs on common human hepatic cytochrome P450 and UDP-glucuronosyltransferase enzymes. Drug Metab Dispos, 2017,45(9):1035-1043. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
